<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) January 17, 2001
Genetronics Biomedical, Ltd.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
British Columbia, Canada 0-29608 33-0024450
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
11199 Sorrento Valley Road, San Diego California 92121-1334
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (858) 597-6006
Not Applicable
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE> 2
ITEM 5. OTHER EVENTS.
On January 17, 2001, Genetronics Biomedical, Ltd. completed an offering of
6,267,500 common shares at a price of Canadian $1.35 per share. The shares were
primarily purchased by existing shareholders of the Company. Exhibit 99 is a
press release issued to announce the completion of this financing.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
<TABLE>
<CAPTION>
Exhibit
No. Description
------- -----------
<S> <C>
99 Press release issued January 17, 2001
</TABLE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENETRONICS BIOMEDICAL, LTD.
Date: January 17, 2001 By: /s/ Mervyn J. McCulloch
--------------------------
Chief Financial Officer
<PAGE> 3
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
No. Description
------- -----------
<S> <C>
99 Press release issued January 17, 2001
</TABLE>
